KR100810770B1 - 질병에의 면역학적 개입을 위한 합성 다당류 항원 - Google Patents

질병에의 면역학적 개입을 위한 합성 다당류 항원 Download PDF

Info

Publication number
KR100810770B1
KR100810770B1 KR1020067005302A KR20067005302A KR100810770B1 KR 100810770 B1 KR100810770 B1 KR 100810770B1 KR 1020067005302 A KR1020067005302 A KR 1020067005302A KR 20067005302 A KR20067005302 A KR 20067005302A KR 100810770 B1 KR100810770 B1 KR 100810770B1
Authority
KR
South Korea
Prior art keywords
compound
formula
cells
inflammatory
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067005302A
Other languages
English (en)
Korean (ko)
Other versions
KR20060057015A (ko
Inventor
래리 크리스 브라스책
존 애스터 쥬니어. 클리브랜드
캐트린 앤 테일러
네일 토마스 블랙번
안젤리카 레지나 크래프트
찰스 엘리스 코헨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20060057015A publication Critical patent/KR20060057015A/ko
Application granted granted Critical
Publication of KR100810770B1 publication Critical patent/KR100810770B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020067005302A 2003-09-17 2004-09-15 질병에의 면역학적 개입을 위한 합성 다당류 항원 Expired - Fee Related KR100810770B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50378403P 2003-09-17 2003-09-17
US60/503,784 2003-09-17

Publications (2)

Publication Number Publication Date
KR20060057015A KR20060057015A (ko) 2006-05-25
KR100810770B1 true KR100810770B1 (ko) 2008-03-07

Family

ID=34434862

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067005302A Expired - Fee Related KR100810770B1 (ko) 2003-09-17 2004-09-15 질병에의 면역학적 개입을 위한 합성 다당류 항원

Country Status (8)

Country Link
US (1) US8129518B2 (enExample)
EP (1) EP1664127A1 (enExample)
JP (1) JP2007505905A (enExample)
KR (1) KR100810770B1 (enExample)
CN (1) CN100554279C (enExample)
AU (1) AU2004280329B2 (enExample)
CA (1) CA2538418A1 (enExample)
WO (1) WO2005035588A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874343A4 (en) * 2005-04-19 2009-07-22 Lilly Co Eli MONOVALENT AND MULTIPURPOSE SYNTHETIC POLYSACCHARIDIC ANATIGENS FOR IMMUNOLOGICAL INTERVENTION IN PATHOLOGY
WO2007136738A2 (en) * 2006-05-19 2007-11-29 Trustees Of Boston University Novel hydrophilic polymers as medical lubricants and gels
WO2008067026A2 (en) 2006-09-29 2008-06-05 Michigan Technological University Purification of synthetic oligomers
RU2349339C1 (ru) * 2007-07-12 2009-03-20 Валентина Васильевна Малиновская Средство, обладающее иммуномодулирующим, антивирусным, антибактериальным, антиоксидантным, мембраностабилизирующим, стимулирующим регенерацию хрящевой и соединительной ткани свойствами
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
FR2954703B1 (fr) * 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US20110251156A1 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011146910A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
US9243023B2 (en) 2010-09-27 2016-01-26 Michigan Technological University Purification of synthetic oligonucleotides
US9180173B2 (en) * 2013-12-09 2015-11-10 Stephanie D. Neider Methods of treating psoriasis using candida antigen
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
US10765696B2 (en) 2015-06-10 2020-09-08 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
CA3019445A1 (en) 2016-03-30 2017-12-14 Synovo Gmbh Detecting microbial infection in wounds
EP3295926A1 (en) 2016-09-19 2018-03-21 Institut Univ. de Ciència i Tecnologia, S.A. Exopolysaccharide-protein complex, a method of preparing said complex and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186194A (en) 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
WO1999060155A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab A scintillation proximity assay for the detection of peptidoglycan synthesis
WO2002085929A1 (en) * 2001-04-18 2002-10-31 Eli Lilly And Company Process for preparing lipid ii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU727647A1 (ru) 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US5834435A (en) * 1996-11-27 1998-11-10 Slesarev; Vladimir I. Inhibition of TNF-α pleiotropic and cytotoxic effects
US20010034325A1 (en) * 2000-03-07 2001-10-25 Slesarev Vladimir I. Dietary modulators of gamma glutamyl transpeptidase
MXPA02010263A (es) * 2000-04-18 2004-08-12 Lilly Co Eli Proceso para preparar lipido ii.
US7629313B2 (en) 2002-03-08 2009-12-08 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathologies
US20040258779A1 (en) * 2003-06-06 2004-12-23 Pinegrin Boris V. Dietary and pharmaceutical compositions for treatment of anemia, thrombocytopenia, and leukopenia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186194A (en) 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
WO1999060155A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab A scintillation proximity assay for the detection of peptidoglycan synthesis
WO2002085929A1 (en) * 2001-04-18 2002-10-31 Eli Lilly And Company Process for preparing lipid ii

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문(Tetrahedron Letters, vol.42, no.43, pp.7613-7616)

Also Published As

Publication number Publication date
CN1867589A (zh) 2006-11-22
CN100554279C (zh) 2009-10-28
CA2538418A1 (en) 2005-04-21
JP2007505905A (ja) 2007-03-15
HK1099319A1 (zh) 2007-08-10
AU2004280329B2 (en) 2011-03-24
EP1664127A1 (en) 2006-06-07
KR20060057015A (ko) 2006-05-25
US20070041986A1 (en) 2007-02-22
WO2005035588A1 (en) 2005-04-21
AU2004280329A1 (en) 2005-04-21
US8129518B2 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
US20100310470A1 (en) Immunomodulatory polymeric antigens for treating inflammatory pathologies
KR100810770B1 (ko) 질병에의 면역학적 개입을 위한 합성 다당류 항원
Su et al. Chiral polypeptide nanoparticles as nanoadjuvants of nanovaccines for efficient cancer prevention and therapy
Boulé et al. Toll-like receptor 9–dependent and–independent dendritic cell activation by chromatin–immunoglobulin G complexes
JP2012515722A (ja) 抗原特異的寛容の誘導のための組成物および方法
KR20220035425A (ko) 자가면역 질환 치료용 조성물 및 방법
Roth-Walter et al. M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy
JP2023036860A (ja) 腫瘍浸潤ｔ細胞集団を生成する方法
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
EP2989121B1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
Zhang et al. Fucoidan from Durvillaea Antarctica enhances the anti-cancer effect of anti-PD-L1 antibody by activating dendritic cells and T cells
AU2011343253B2 (en) Method for suppressing an immune response
Sands et al. Steroid–peptide immunoconjugates for attenuating T cell responses in an experimental autoimmune encephalomyelitis murine model of multiple sclerosis
US20090214598A1 (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
KR100922675B1 (ko) 면역아쥬반트
CA3104182C (en) Immunomodulatory peptides and methods for modulating the immune system in a subject
AU2011203013A1 (en) Synthetic polysaccharide antigens for immunological intervention in disease
AU2018250926A1 (en) Methods to produce peptides, polypeptides or cells for modulating immunity
HK1099319B (en) Synthetic polysaccharide antigens for immunological intervention in disease
US20160158330A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
CN109563481A (zh) 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
Khiewkamrop Generation of tolerogenic dendritic cells from Fcgr2b deficient lupus-prone mice for the model of SLE therapy
HK1191562A (en) Method for suppressing an immune response
Buyuktimkin Utilizing Antigenic Peptide and Adhesion Molecule Conjugates to Suppress Autoimmune Disease in Animal Models
Li et al. Xiao-Li Li1, Heng Li1, Min Zhang1, Hua Xu1, 2, Long-Tao Yue3, Xin-Xin Zhang4, Shan Wang1, Cong-Cong Wang1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080410

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1008107700000

Gazette reference publication date: 20080307

FPAY Annual fee payment

Payment date: 20110218

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120229

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120229

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000